Gorilla Technology (Nasdaq: GRRR) has signed a definitive deal to acquire Thai innovators CNS and CANS, adding over 200 enterprise clients and a powerful AI-powered customer engagement platform to its portfolio. With the ASEAN Edge AI and cybersecurity market projected to top $6.8B by 2027, the move positions Gorilla to capture recurring revenue across telecom, smart cities, and public safety infrastructure.

Alliance Entertainment (Nasdaq: AENT) has secured exclusive North American distribution rights for Master Replicas, bringing iconic sci-fi collectibles from franchises like Star Trek, Dune, and Blade Runner to its expansive B2B network. The partnership strengthens Alliance’s position in the $100B+ global collectibles market by pairing premium licensed products with unmatched retail and e-commerce reach.

In a shareholder letter, Calidi Biotherapeutics (NYSE American: CLDI) CEO Eric Poma outlines a transformative 2025, highlighting the company’s strategic refocus on its RedTail platform—an engineered enveloped virus designed for systemic delivery of gene therapies to metastatic tumors. With promising preclinical data and IND-enabling studies underway for lead candidate CLD-401, Calidi is eyeing a late 2026 IND filing and expanding strategic partnerships to tap into the multi-billion-dollar oncology market.

bioAffinity Technologies (Nasdaq: BIAF) has strengthened its global IP position with a newly granted Chinese patent covering its siRNA-based therapeutic targeting CD320 and LRP2 receptors—shown in vitro to selectively kill cancer cells from various tumor types without harming healthy tissue. The company is advancing this platform for topical use in skin cancers, complementing its flagship CyPath® Lung diagnostic as it expands into high-impact, RNA-driven oncology treatments.